12:00 AM
Feb 13, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

CVac: Phase II/III started

Prima BioMed began the double-blind, placebo-controlled, international Phase II/III CANVAS trial to evaluate intradermal CVac over 44 weeks in about 800 women who are in complete remission after completing first-line treatment of surgery followed by chemotherapy. Patients will receive CVac every 4 weeks...

Read the full 191 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >